Elective cardioversion of atrial fibrillation is safe without transesophageal echocardiography in patients treated with non-vitamin K antagonist oral anticoagulants: Multicenter experience

BACKGROUND: Current guidelines recommend electrical cardioversion (ECV) in patients with atrial fibrillation (AF) after at least 3 weeks of adequate non-vitamin K antagonist oral anticoagulant (NOAC) treatment without prior transesophageal echocardiography (TEE). However, in clinical practice in som...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorczyca, Iwona, Uziębło-Życzkowska, Beata, Szpotowicz, Anna, Chrapek, Magdalena, Krzesiński, Paweł, Bielecka, Bernadetta, Woronowicz-Chróściel, Agnieszka, Wałek, Paweł, Krzciuk, Małgorzata, Wożakowska-Kapłon, Beata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2023
Materias:
Clinical Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129268/
https://www.ncbi.nlm.nih.gov/pubmed/33634847
http://dx.doi.org/10.5603/CJ.a2021.0010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129268/
https://www.ncbi.nlm.nih.gov/pubmed/33634847
http://dx.doi.org/10.5603/CJ.a2021.0010

Ejemplares similares